Ashland/$ASH

1D1W1MYTD1Y5YMAX

About Ashland

Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Ticker
$ASH
Sector
Materials
Primary listing
NYSE
Employees
2,900

Ashland Metrics

BasicAdvanced
$3.2B
61.33
$1.15
0.41
$1.67
2.38%

What the Analysts think about Ashland

Analyst ratings (Buy, Hold, Sell) for Ashland stock.
Analyst projections of the future price of Ashland stock.

Bulls say / Bears say

Ancora Alternatives has built a significant stake in Ashland and is pushing for a sale that could unlock at least 30% upside to the share price, serving as a strong catalyst (Reuters (investing.com)).
Ashland is reported to be nearing a settlement with activist investor Ancora that would add two directors to its board and establish a capital allocation committee, strengthening governance and capital discipline (Bloomberg News via Investing.com (investing.com)).
A Bloomberg report indicates Ashland is exploring a strategic sale after receiving takeover interest, highlighting the likelihood of an M&A process that could deliver a premium to shareholders (Bloomberg (bloomberg.com)).
Ashland lowered its adjusted EPS growth outlook to low-to-mid-single-digit growth from mid-to-high-single-digit growth due to a higher tax rate and unfavorable discrete items, signaling earnings headwinds (Reuters via TradingView News (tradingview.com)).
Activist Ancora stands ready to launch a proxy fight by September if Ashland does not pursue a strategic sale, creating governance uncertainty and potential management distraction (Reuters (investing.com)).
Ancora’s presentation attributed Ashland’s lackluster performance and 24% share-price decline under CEO Guillermo Novo’s transformation program to flawed execution of non-core divestitures and cost-cutting initiatives since 2019 (Reuters (investing.com)).
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.

Ashland Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Ashland Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Ashland

AllEURUSDGBP
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.